Hong-Hong Yan

发表

Multiple primary malignancies involving lung cancer

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2015, BMC Cancer.

Decreased Expression of SOX7 is Correlated with Poor Prognosis in Lung Adenocarcinoma Patients

B. Li, Yangde Zhang, Bo-yun Huang, 2012, Pathology & Oncology Research.

The Unique Spatial‐Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104)

Ying Cheng, Yi-long Wu, Zhidong Liu, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Concomitant genetic alterations having greater impact on the clinical benefit of EGFR‐TKIs in EGFR‐mutant advanced NSCLC than BIM deletion polymorphism

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2020, Clinical and translational medicine.

Posttreatment plasma VEGF levels may be associated with the overall survival of patients with advanced non-small cell lung cancer treated with bevacizumab plus chemotherapy

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2012, Medical Oncology.

Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer.

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Visceral pleural invasion in T1 tumors (≤3 cm), particularly T1a, in the eighth tumor-node-metastasis classification system for non-small cell lung cancer: a population-based study.

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2019, Journal of thoracic disease.

Polymorphism of Rs9387478 Correlates with Overall Survival in Female Nonsmoking Patients with Lung Cancer

N. Rothman, Yi-long Wu, Jin-Ji Yang, 2016, The International journal of biological markers.

Clinical outcomes of EGFR +/ METamp+ vs. EGFR +/ METamp‐ untreated patients with advanced non‐small cell lung cancer

Jin-Ji Yang, Xuchao Zhang, Jian Su, 2022, Thoracic cancer.

Clinical outcomes of EGFR +/ MET amp + vs. EGFR +/

Jin-Ji Yang, Xuchao Zhang, Jian Su, 2022, Thoracic Cancer.

Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II-IIIA (N1-N2) EGFR-mutant non-small-cell lung cancer: Results from the ADJUVANT (CTONG1104) study.

Ying Cheng, Yi-long Wu, Zhidong Liu, 2020, Lung cancer.

Prognostic features and comprehensive genomic analysis of NF1 mutations in EGFR mutant lung cancer patients

Xuchao Zhang, Hong-Hong Yan, Si-pei Wu, 2022, Cancer medicine.

TNM stages inversely correlate with the age at diagnosis in ALK-positive lung cancer.

Chao Zhang, Xue-Ning Yang, W. Zhong, 2019, Translational lung cancer research.

Impact of menopausal status and HER-2/neu protein on efficacy of EGFR-TKI in EGFR mutant patients with non-small cell lung cancer

Yi-long Wu, W. Zhong, S. An, 2018, Journal of Cancer.

Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Males, Smokers, and Non-adenocarcinoma Lung Cancer in Patients with EGFR Mutations

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2013, The International journal of biological markers.

MET Expression Plays Differing Roles in Non–Small-Cell Lung Cancer Patients with or without EGFR Mutation

Yi-long Wu, S. An, Jian Su, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Soluble c‐Met Levels Correlated With Tissue c‐Met Protein Expression in Patients With Advanced Non–Small‐Cell Lung Cancer

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2017, Clinical lung cancer.

Multiple primary malignancies involving lung cancer

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2015, BMC Cancer.

[High resolution melting analysis for detecting p53 gene mutations in patients with non-small cell lung cancer].

Yilong Wu, S. An, Xuchao Zhang, 2011, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Venous thromboembolism risk factors in Chinese non-small cell lung cancer patients

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2015, Supportive Care in Cancer.

Clinical Utility of Cerebrospinal Fluid Cell‐Free DNA as Liquid Biopsy for Leptomeningeal Metastases in ALK‐Rearranged NSCLC

Yi-long Wu, Jin-Ji Yang, S. Chuai, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

High expression of truncated GLI3 is associated with poor overall survival in patients with non-small cell lung cancer.

Yi-long Wu, Chongrui Xu, S. An, 2013, Cancer biomarkers : section A of Disease markers.

Biomarker-Driven Studies With Multi-targets and Multi-drugs by Next-Generation Sequencing for Patients With Non-Small-Cell Lung Cancer: An Open-Label, Multi-center, Phase II Adaptive Umbrella Trial and a Real-World Observational Study (CTONG1702&CTONG1705).

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2022, Clinical lung cancer.

Clinical Modes of EGFR Tyrosine Kinase Inhibitor Failure and Subsequent Management in Advanced Non-Small Cell Lung Cancer

Yi-long Wu, Jiyun Yang, Hong-Hong Yan, 2012 .

Deep learning-based growth prediction for sub-solid pulmonary nodules on CT images

Xue-Ning Yang, W. Zhong, Q. Nie, 2022, Frontiers in Oncology.

Supraclavicular lymph node incisional biopsies have no influence on the prognosis of advanced non-small cell lung cancer patients: a retrospective study

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2017, World Journal of Surgical Oncology.

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.

Ying Cheng, Yi-long Wu, Zhidong Liu, 2018, The Lancet. Oncology.

BRAIN study: it is hard to draw a conclusion - Authors' reply.

Jin-Ji Yang, Hong-Hong Yan, Yi-Long Wu, 2017, The Lancet. Respiratory medicine.

Organ-specific efficacy in advanced non-small cell lung cancer patients treated with first-line single-agent immune checkpoint inhibitors

Chongrui Xu, Q. Gou, Hong-Hong Yan, 2022, Chinese medical journal.

A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival.

Yi-long Wu, Jin-Ji Yang, Chao Zhang, 2022, Lung cancer.

Reply to A. Tateishi et al.

Yi-long Wu, W. Zhong, Hong-Hong Yan, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastases.

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2019, Lung cancer.

Genomic characteristics and drug screening among organoids derived from non‐small cell lung cancer patients

X. Yi, C. Deng, Yi-long Wu, 2020, Thoracic cancer.

Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study

Yi-long Wu, Dehua Wu, Hong-bo Zhu, 2020, Journal for immunotherapy of cancer.

Expression of MET and SOX2 genes in non-small cell lung carcinoma with EGFR mutation.

Jianxin Ye, Yan Liu, Hong-Hong Yan, 2011, Oncology reports.

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Jian Su, Qing Zhou, Hai-Yan Tu, 2016, Clinical Cancer Research.

Plasma dynamic monitoring of soluble c-Met level for EGFR-TKI treatment in advanced non-small cell lung cancer

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2016, Oncotarget.

Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma

X. Yi, Yi-long Wu, W. Zhong, 2020, EBioMedicine.

Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes

Ying Cheng, Yi-long Wu, Jin-Ji Yang, 2021, Nature Communications.

Final overall survival for CSLC 0501: Phase 3 study of adjuvant versus neoadjuvant chemotherapy with docetaxel combined carboplatin for resectable stageIB-IIIA non-small cell lung cancer.

Yi-long Wu, Xue-Ning Yang, W. Zhong, 2018 .

Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study

Jin-Ji Yang, Chongrui Xu, Xuchao Zhang, 2023, Cell reports. Medicine.

Genomic Signatures Define Three Subtypes of EGFR-Mutant Stage II-III NSCLC With Distinct Adjuvant Therapy Outcomes

W. Mao, Ying Cheng, Yi-long Wu, 2021 .

Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial

Ying Cheng, Yi-long Wu, Jin-Ji Yang, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A New Prognostic Index Combines the Metabolic Response and RECIST 1.1 to Evaluate the Therapeutic Response in Patients With Non-Small Cell Lung Cancer

W. Zhong, Yilong Wu, Hong-Hong Yan, 2020, Frontiers in Oncology.

Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study.

Ying Cheng, Yi-long Wu, Jin-Ji Yang, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2015, Journal of Hematology & Oncology.

A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer.

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2017, Lung cancer.

Anaplastic Lymphoma Kinase Variants and the Percentage of ALK-Positive Tumor Cells and the Efficacy of Crizotinib in Advanced NSCLC.

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2016, Clinical lung cancer.

MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2021, Experimental Hematology & Oncology.

Effects of epidermal growth factor receptor‐tyrosine kinase inhibitors alone on EGFR‐mutant non‐small cell lung cancer with brain metastasis

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2016, Thoracic cancer.

KRAS Mutation in Patients with Lung Cancer: A Predictor for Poor Prognosis but Not for EGFR-TKIs or Chemotherapy

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2013, Annals of Surgical Oncology.

A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer.

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2013, Lung cancer.

Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status

T. Mok, Yi-long Wu, Jin-Ji Yang, 2012, PloS one.

The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2016, Oncotarget.

Predictive and Prognostic Potential of TP53 in Patients With Advanced Non-Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial (CTONG 0901).

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2020, Clinical lung cancer.

Integrated histological and molecular analyses of rebiopsy samples at osimertinib progression improve post-progression survivals: A single-center retrospective study.

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2020, Lung cancer.

Retrospective study on bevacizumab in the treatment of non-small cell lung cancer with brain metastases

Yi-long Wu, Jin-Ji Yang, Hong-Hong Yan, 2019, International Journal of Clinical Oncology.

A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002).

Ying Cheng, Yi-long Wu, Jin-Ji Yang, 2019, European journal of cancer.

Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression

Jian Su, Jun Zhao, Qing Zhou, 2018, BMC Cancer.

The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma

Jin-Ji Yang, Yilong Wu, Chongrui Xu, 2016, Oncotarget.

Comparing overall survival between first generation EGFR-TKIs and chemotherapy in lung cancer patients with Del19/L858R

Jin-Ji Yang, Yilong Wu, Y. Lei, 2016, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

Prognostic significance of genotype and number of metastatic sites in advanced non-small-cell lung cancer.

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2014, Clinical lung cancer.

A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805).

Ying Cheng, Yi-long Wu, Jin-Ji Yang, 2014, Lung cancer.

Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2016, Journal of Hematology & Oncology.

EGFR mutations in early‐stage and advanced‐stage lung adenocarcinoma: Analysis based on large‐scale data from China

Xing Gao, Chongrui Xu, Hong-Hong Yan, 2018, Thoracic cancer.

EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas.

T. Mok, Yi-long Wu, Jin-Ji Yang, 2012, The oncologist.

Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level

Jin-Ji Yang, Yilong Wu, Chongrui Xu, 2019, BMC Cancer.

Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.

Ying Cheng, Yi-long Wu, Jin-Ji Yang, 2017, The Lancet. Respiratory medicine.

Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations

Yi-long Wu, Jin-Ji Yang, Hong-Hong Yan, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Reduced chemotherapy sensitivity in EGFR-mutant lung cancer patient with frontline EGFR tyrosine kinase inhibitor.

Yi-long Wu, W. Zhong, Chongrui Xu, 2014, Lung cancer.

Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials.

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2014, Lung cancer.

Disease Flare After EGFR Tyrosine Kinase Inhibitor Cessation Predicts Poor Survival in Patients with Non-small Cell Lung Cancer

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2013, Pathology & Oncology Research.

Gene co-expression modules integrated with immunoscore predicts survival of non-small cell lung cancer.

Yi-long Wu, W. Zhong, M. Cheng, 2020, Cancer treatment and research communications.

Single Nucleotide Polymorphisms in VTI1A Gene Contribute to the Susceptibility of Chinese Population to Non-Small Cell Lung cancer

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2015, The International journal of biological markers.

Clinical features and intervention timing in patients with pregnancy-associated non-small-cell lung cancer

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2021, Journal of thoracic disease.

Detecting the spectrum of multigene mutations in non-small cell lung cancer by Snapshot assay

Yi-long Wu, W. Zhong, S. An, 2014, Chinese journal of cancer.

Gefitinib (G) versus vinorelbine+cisplatin (VP) as adjuvant treatment in stage II-IIIA (N1-N2) non-small-cell lung cancer (NSCLC) with EGFR-activating mutation (ADJUVANT): A randomized, Phase III trial (CTONG 1104).

Ying Cheng, Yi-long Wu, Zhidong Liu, 2017 .

Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non–Small Cell Lung Cancer

X. Yi, Jin-Ji Yang, Xue-Ning Yang, 2022, Cancer discovery.

A family history of cancer and lung cancer risk in never-smokers: A clinic-based case-control study.

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2015, Lung cancer.

High expression of survivin predicts poor prognosis in cervical squamous cell carcinoma treated with paclitaxel and carboplatin

Hong-Hong Yan, Yunzhong Zhang, Yuzhen Guo, 2019, Medicine.

P1.01-018 Acquired Resistance to Crizotinib in Advanced NSCLC with De Novo MET Overexpression

Jin-Ji Yang, W. Zhong, Z. Xie, 2017 .

Mixed Responses to Systemic Therapy Revealed Potential Genetic Heterogeneity and Poor Survival in Patients with Non-Small Cell Lung Cancer.

Yi-long Wu, W. Zhong, Hong-Hong Yan, 2017, The oncologist.

Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer.

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2018, Lung cancer.

RRM1 single nucleotide polymorphism -37C→A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy

Yi-long Wu, Xuchao Zhang, S. Dong, 2010, Journal of hematology & oncology.

Recursive partitioning analysis of patients with oligometastatic non-small cell lung cancer: a retrospective study

Yi-long Wu, W. Zhong, Q. Nie, 2019, BMC Cancer.

Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2019, EBioMedicine.

Lung cancer treatment disparities in China: a question in need of an answer.

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2014, The oncologist.

Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial

Ying Cheng, Jin-Ji Yang, Xue-Ning Yang, 2023, Signal Transduction and Targeted Therapy.

Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study

Ying Cheng, Yi-long Wu, Zhidong Liu, 2021, JTO clinical and research reports.

Is 18F-fluorodeoxyglucose positron emission tomography-based metabolic response superior to Response Evaluation Criteria In Solid Tumors-based response after two cycles of platinum-based chemotherapy in predicting clinical outcome of untreated patients with advanced non-small cell lung cancer?

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2011, Nuclear medicine communications.

Feasibility of computed tomography‐guided core needle biopsy in producing state‐of‐the‐art clinical management in Chinese lung cancer

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2014, Thoracic cancer.

Clinical efficacy of crizotinib in Chinese patients with ALK-positive non-small-cell lung cancer with brain metastases.

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2015, Journal of thoracic disease.

Sintilimab versus pembrolizumab in monotherapy or combination with chemotherapy as first-line therapy for advanced non–small cell lung cancer: Results from phase 2, randomized clinical trial (CTONG1901).

Jin-Ji Yang, Xuchao Zhang, Hong-Hong Yan, 2022, Journal of Clinical Oncology.

A robust gene expression-based prognostic risk score predicts overall survival of lung adenocarcinoma patients

A. Snijders, J. Mao, En-guo Chen, 2017, Oncotarget.

Three‐dimensional printed navigational template for localizing small pulmonary nodules: A case‐controlled study

Yi-long Wu, Xue-Ning Yang, W. Zhong, 2020, Thoracic cancer.

Comparison of three mathematical prediction models in patients with a solitary pulmonary nodule.

Xue-Ning Yang, Hong-Hong Yan, Xuan Zhang, 2014, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[Forecasting model of risk of cancer in lung cancer pedigree in a case-control study].

Xue-Ning Yang, W. Zhong, Yilong Wu, 2011, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Development and Validation of a 18F-FDG PET/CT-Based Clinical Prediction Model for Estimating Malignancy in Solid Pulmonary Nodules Based on a Population With High Prevalence of Malignancy.

W. Zhong, Hong-Hong Yan, Jun-Tao Lin, 2020, Clinical lung cancer.

Circulating tumor cells dynamics during chemotherapy predict survival and response in advanced non-small-cell lung cancer patients

Jin-Ji Yang, W. Feng, Xuchao Zhang, 2023, Therapeutic advances in medical oncology.

Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2018, BMC Cancer.

Recursive partitioning analysis of patients with oligometastatic non-small cell lung cancer: a retrospective study

Yi-long Wu, W. Zhong, Q. Nie, 2019, BMC Cancer.

Accidental invisible intrathoracic disseminated pT4-M1a: a distinct lung cancer with favorable prognosis.

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2015, Journal of thoracic disease.

Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2016, Oncotarget.

Randomized Trial of an Improved Drainage Strategy vs Routine Chest Tube after Lung Wedge Resection.

Yi-long Wu, Xue-Ning Yang, W. Zhong, 2020, The Annals of thoracic surgery.

Molecular characteristics and clinical outcomes of EGFR exon 19 indel subtypes to EGFR TKIs in NSCLC patients

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2017, Oncotarget.

Principles of biopsy in suspected lung cancer: priority still based on invasion in the era of targeted therapy?

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2013, Journal of thoracic disease.

First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial

Yangqiu Li, Jin-Ji Yang, Chongrui Xu, 2023, Nature Network Boston.

A randomized phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in locally advanced or metastatic squamous cell carcinoma of lung

Ying Cheng, Yi-long Wu, Jin-Ji Yang, 2014, BMC Cancer.

PL03.05: BRAIN: A Phase III Trial Comparing WBI and Chemotherapy with Icotinib in NSCLC with Brain Metastases Harboring EGFR Mutations (CTONG 1201)

Ying Cheng, Yi-long Wu, Chengping Hu, 2017 .

A Clinical Model to Estimate the Pretest Probability of Lung Cancer, Based on 1198 Pedigrees in China

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A comprehensive model of genetic-features predicts outcome of personalized adjuvant treatment in resected EGFR-mutant stage II-IIIA NSCLC: Results from a phase III trial (CTONG 1104-ADJUVANT)

W. Mao, Q. Wang, W. Zhong, 2019, Annals of Oncology.

A phase II trial comparing pemetrexed with gefitinib as the second-line treatment of nonsquamous NSCLC patients with wild-type EGFR (CTONG0806).

Ying Cheng, Yi-long Wu, Jin-Ji Yang, 2013 .

Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level

Jin-Ji Yang, Yilong Wu, Chongrui Xu, 2019, BMC Cancer.

Prophylactic air‐extraction strategy after thoracoscopic wedge resection

Xue-Ning Yang, W. Zhong, Q. Nie, 2018, Thoracic cancer.

The spatiotemporal evolution of EGFR C797S mutation in EGFR-mutant non-small cell lung cancer: opportunities for third-generation EGFR inhibitors re-challenge.

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2019, Science bulletin.

Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial.

Yi-long Wu, W. Feng, W. Zhong, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.